glp-1 masld Two Pediatric Publications: Call for Action and Use of RAs Randomised trial comparing weight loss

At Pine Point Medical , our medically supervised programs focus on personalized care, sustainable habits, and long-term wellness

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

Side effect tolerance plays a role

Because higher doses of GLP-1s commonly cause nausea, bloating, or digestive discomfort, microdosing may make the therapy more tolerable without sacrificing potential benefits

we ensure our clients achieve healthy, sustainable results by using advanced tools to track fat loss and preserve muscle

These medications are often used for weight loss in people without diabetes